Agios Pharmaceuticals (AGIO)

• Market cap: $1.7B
• 1 day: 1.02%
• 5 days: 3.02%
• 1 month: 17.15%
• 3 months: -5.33%
• 6 months: -1.99%
• Year to date: 5.3%
• 1 year: -5.23%
• 5 years: -49.88%
• 10 years: -46.34%
• Sector: Healthcare
• Industry: Biotechnology

About: Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

Employees: 540